treatment
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
May 25, 2021
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant
Key Points
Donor-derived T cells with native specificity for multiple myeloid leukemia antigens can be expanded ex vivo.
Infusion of mLSTs after HCT is well tolerated and produces antileukemia effects.
Venetoclax
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.
Aplastic Anemia and MDS International Foundation and NORD Launch New Natural History Study of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Global PNH Patient Registry
The Global PNH Patient Registry is a collaborative effort between the Aplastic Anemia and MDS International Foundation (AAMDSIF) and the National Organization for Rare Disorders (NORD®) to study PNH.
RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory
Haploidentical Transplant for MDS
Dr. Shaffer provides an overview of the haploidentical transplant process and discusses how this treatment option might be right for some MDS patients.
What's My Mutation? Understanding the Risks for Low/Moderate Risk MDS Patients: Spring 2021 Conference
Tiffany Tanaka, MD (UC San Diego Health) helps MDS patients understand the most common mutations and how genetic testing can help patients get the best possible treatment.
Session recorded as part of the Spring 2021 Virtual Patient & Family Conference.
Update for Josh: A Change in Treatment is only a Little Unsettling
Person's Name:
Joshua Maliczowski
2021 Treatment update
Bone Marrow Disease(s):
Content source: